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Injust six years after the initial description ofthe acquired immunodeficiency syndrome, much
has been learned about the etiologic agent, the human immunodeficiency virus. The pathogenic
mechanisms utilized by this virus to infect selectively and persistently T4+ lymphocytes and
monocyte/macrophages, leading to immunodeficiency and neurologic dysfunction, are slowly
becoming clear. Better understanding of the pathogenesis of human immunodeficiency virus
infection isessential for the rationaldesignoftherapeutic and preventivestrategies tocombat this
deadly virus.
The etiologic agent of the acquired immunodeficiency syndrome (AIDS) is now
known as the human immunodeficiency virus (HIV). This virus has a diameter of
approximately 100 nm, a lipid envelope, and a dense core consisting of core proteins,
RNA-dependent DNA polymerase (reverse transcriptase), and genomic RNA. In
addition to thestandard retroviral gag,pol, and envgenes, HIV encodes for at least five
other genes. Two multi-exon genes, tat and trs/art, are important transcriptional or
translational regulators of HIV synthesis. The functional roles of three additional
genes-sor, 3'orfand R-have not been clearly established.
HIV INFECTION OF T4+ LYMPHOCYTES
The hallmark of the immunodeficiency in AIDS is a depletion of T4+ helper-
inducer lymphocytes [1]. This defect is primarily the result ofthe selective tropism of
HIV. HIV selectively replicates in T4+ lymphocytes, but not in T8+ lymphocytes [2].
In addition, HIV infection of T4+ cells in vitro can be blocked by monoclonal
antibodies directed against specific epitopes on the T4 molecule [3-5]. In binding
experiments ofHIV to T4+ cells, McDougal et al. [6] foundthat immunoprecipitation
of the T4 antigen resulted in the co-precipitation of gpl20, the major envelope
glycoprotein of HIV. Conversely, immunoprecipitation of gpl20 co-precipifated the
T4 molecule. Moreover, intracellular complexing of T4 and gpl20 has also been
demonstrated [7]. Recent studies by Maddon et al. [8] also support this idea. Certain
human epithelial cells do not express the T4 antigen and are resistant to HIV infection.
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When the T4 gene is inserted into these cells, however, they become susceptible to
HIV. Productive infection occurs and the infected cells fuse to form multinucleated
giant cells and have shortened survival. The studies cited clearly establish the T4
molecule as the receptor for HIV.
After specific binding to the target cell, HIV enters the cell and is uncoated,
although the mechanism of this process has not been clearly defined. One study has
suggested that HIV entry occurs via receptor-mediated endocytosis [8]. A more
extensiveanalysis by Stein et al., however, demonstrated pH-independent direct fusion
ofthe virus envelope to the plasma membrane [9]. Following penetration, the genomic
RNA is then transcribed into DNA by the reverse transcriptase. Subsequently, the
DNA is circularized and integrated into the host chromosome by a virus-encoded
enzyme (integrase, a product ofthepolgene) during cell division. Interestingly, much
ofthe DNA ofHIV remains unintegrated in thecytoplasm. The HIV replication cycle
is restricted at this stage until the infected cell is activated. In vitro, this is achieved by
mitogenic, antigenic, or allogeneic stimulation [5,10] or by the addition ofcytokines.
Upon activation, transcription occurs, followed by protein synthesis with post-
translational processing, including protein cleavage and glycosylation. Viral proteins
and genomic RNA are then assembled at the cell surface, and mature virions are
formed by budding.
With HIV replication, theT4+ cell is killed by an as yet unclear mechanism. Could
one of the five novel genes of HIV be involved in cell killing? Tat and trs/art are
essential regulators of viral synthesis and are unlikely to be the direct cause of cell
death [11-15]. Base changes or deletions have been introduced in sor and 3'orf, but
these mutants retained their cytopathic effect [16-19], although 3'orf mutations
resulted in higher levels of virus replication, suggesting that this gene has a negative
regulatory role in HIV expression [17]. There is currently no evidence to implicate sor
or 3'orfin cell killing. The role ofthe "R" gene in this process is unknown [20].
It seems likely that HIV envelope glycoproteins play an important role in killing
T4+ cells, probably through cell-cell fusion. Fusion is observed when viral particles
bud from the cell membrane of infected T4+ cells. This process results in the
formation of syncytia (multinucleated giant cells), which then develop ballooning
cytoplasm and promptly die. Lifson et al. haveshown that thesesyncytia arecomposed
of both infected and uninfected T4+ cells [21]. Uninfected T4+ cells are recruited
into the syncytia because the gpl20 on the budding virions specifically binds the T4
molecules on uninfected cells. Once bound, the fusion process is probably mediated by
a different domain on the HIV envelope, possibly the transmembrane protein (gp41)
since mutations in this region of env abolished the fusogenic property of HIV [19].
Furthermore, Sodroski et al. [22] and Lifson et al. [23] demonstrated syncytia
formation by inserting only env into T4+ cells. Insertion ofenv into T4- cells did not
inducesyncytia. It appears that notonly theglycosylated HIVenvelope but also the T4
molecule is necessary for the fusion process, which provides a mechanism for killing
infected, as well as uninfected, T4+ cells. This process is not likely to be the only
mechanism, however, as normal peripheral blood lymphocytes are killed in vitro by
HIV with little or no formation of syncytia. One would need to postulate that fusion
can also involve different parts ofthe plasma membrane ofa single HIV-infected cell.
This process ofautofusion would then lead to membrane permeability changes and cell
death.
Additional mechanisms for T4+ cell depletion in vivo should be considered.
Infected cells expressing HIV on the surface would be recognized and removed by
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FIG. 1. Central role ofthe T4+ lymphocytes in the immune system.
immune surveillance mechanisms. In addition, uninfected T4+ lymphocytes may be
coated by free gpl20, which would also be recognized as foreign and then cleared by
the immune system [24]. HIV-infected lymphocytes may also become more suscepti-
ble to superinfection by other pathogens, such as cytomegalovirus, herpes simplex, or
hepatitis B virus. This type of enhancement, perhaps due to the transactivating
property of the tat gene, may result in faster depletion of the T4+ lymphocyte
population.
TheT4+ helper-inducer lymphocyte is theorchestrator [1] ofthe immune response.
It interacts, directly or indirectly via lymphokines, with monocyte/macrophages,
cytotoxic T cells, natural killer cells, and B cells (Fig. 1). Therefore, even a selective
depletion ofthe T4+ cell population can result in a multitude ofimmunologic deficits
leading to the life-threatening opportunistic infections characteristic ofAIDS.
HIV INFECTION OF MONOCYTE/MACROPHAGES
Monocyte/macrophages may also express the T4 molecule on the cell surface [25],
and several studies have shown that this population can be infected by HIV [26-29].
Ho et al. found that normal blood monocyte/macrophages were infectable by HIV in
vitro, and monocytes from infected persons can harbor the virus in vivo [26]. Similar
findings were obtained by others using monocytes/macrophages derived from blood,
bone marrow, brain, and lung [27-29]. Three groups did not observe cytopathic
changes orcell death in infected monocyte/macrophages [26-28]. In contrast, Gartner
et al. reported syncytia formation, although it was not as prominent as that seen in
infected lymphocytes [29]. The relative refractoriness of infected monocyte/macro-
phages to syncytia formation and cell killing is probably due to a lower surface density
ofT4 molecules. This relative resistance to HIV cytotoxicity raises the possibility that
monocyte/macrophages may serve as a reservoir for virus persistence in the host. In







infection, they may be the first type of cell to be infected by HIV. The infected
monocyte/macrophages may then transmit the virus to susceptible lymphocytes.
HIV infection of monocyte/macrophages may cause a defect in chemotaxis, which
has been described for the monocytes ofAIDS patients [30]. The infection ofalveolar
macrophages may explain the higher incidence of pneumocystis pneumonia in AIDS
patients compared with other immunosuppressed hosts. In addition, it is possible that
monokine release is altered by HIV infection. Enhanced release of interleukin-1 or
tumor necrosis factor could explain chronic fevers in AIDs, since both are endogenous
pyrogens produced by monocytes [31,32]. Tumor necrosis factor is also a potent
catabolic factor [32] and may be important in the pathogenesis of AIDS cachexia,
known as slimdiseasein Africa [33]. The infected monocyte mayalsoserveas avehicle
for transporting HIV to the central nervous system, leading to neurologic dysfunc-
tion.
Subacute encephalitis, also referred to as AIDS encephalopathy or AIDS dementia
complex, is the most common neurologic problem in AIDS [34]. Substantial evidence
is now available to support a direct etiologic role for HIV in this neurologic syndrome.
Shaw et al. first reported the detection ofHIV DNA and RNA in a few affected brains
by Southern hybridization and in situ hybridization, respectively [35]. Subsequently,
Ho and co-workers [36] were often able to isolate HIV from brain or cerebrospinal
fluid ofpatients with subacute encephalitis. The amount ofHIV detected in the neural
tissues frequently exceeded that of blood or other tissues [36]. Intrathecal production
of HIV-specific immunoglobulins in patients with subacute encephalitis [37] has also
beendemonstrated, thus supporting the presenceofHIV in the central nervous system.
These data, together with the similarities between HIV and lentiviruses capable of
inducing encephalitis, strongly support HIV as the causative agent of subacute
encephalitis. This hypothesis in turn suggests that HIV is neurotropic and that the
central nervous system may serve as a sanctuary site for the virus [36].
The predominant cell population in the brain that is infected by HIV appears to be
the monocyte/macrophage. Gabuzda et al. detected HIV antigens in mononuclear
cells in affected brains, and these cells were then morphologically identified as
monocyte/macrophages [38]. Koenig and co-workers also found the monocyte/
macrophage as the cell type in the brain infected by HIV [39]. In addition, they
showed that the multinucleated giant cells seen in subacute encephalitis contained
HIV RNA and expressed monocyte markers as demonstrated by in situ hybridization
and immunohistochemical staining, respectively. Similar results were reported by
Wiley et al. [40], although they also noted HIV infection ofcerebral endothelial cells
and rare involvement of neurons and glial cells. These findings, along with previous
demonstration of HIV infection of monocyte/macrophages in vitro [26-29], suggest
that the infected monocyte/macrophage plays a central role in the pathogenesis ofthe
neurologic disease associated with AIDS.
HIV PERSISTENCE
All HIV-infected persons should beconsidered infected and infectious for life unless
an effective therapy is developed. Several viral properties contribute to this prolonged
persistence. Similar to other retroviruses, HIV DNA is integrated into the host genome
following infection. Therefore, it is difficult to eradicate HIV without also eliminating
the infected T4+ cell. In vivo restriction of viral expression is also seen in HIV
infection. Very little cell-free virus is found in infected persons and less than 1 in
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10,000 circulating lymphocytes express detectable HIV mRNA [41]. Therefore, much
of HIV appears to be restricted (or possibly latent) and not susceptible to immune
clearance mechanisms.
Infected monocyte/macrophages contribute in part to HIV persistence because of
their relative refractoriness to the cytolytic effect of HIV [26-28]. In addition, the
infected monocyte/macrophages in the brain may be protected from many immune
effector cells. These characteristics would allow monocyte/macrophages to serve as an
important reservoir for HIV. A small fraction of infected helper-inducer lymphocytes
can also survive HIV infection [42] and further contribute to virus persistence.
Considerable genomic diversity exists among HIV isolates [43-49] and thevariabil-
ity is most prominent in certain "hypervariable" regions of the external envelope
glycoprotein [49]. It is widely believed without substantiation that immune selection is
responsible for the heterogeneity. Variant viruses may evade immune recognition and
contribute toviral persistence. This possibility has raised concerns about theefficacy of
one vaccine preparation in protecting against many diverse HIV isolates [50]. There is
to date, however, no evidence of HIV variants that are not recognized by the immune
system of infected persons. Indeed, molecular studies of serial isolates from infected
individuals do not support immune selection [51]. Variability of HIV may be better
explained by errors ofreverse transcription coupled with functional selection. Reverse
transcriptase has an error rateseveral orders ofmagnitudegreater than thatofcellular
DNA polymerases [48]. These errors are then amplified by the highly cytolytic nature
of HIV, which results in multiple rounds of infection requiring many reverse-
transcription steps. Other retroviruses, particularly transforming ones, require fewer
rounds of reverse transcription and thus show less diversity [48]. HIV variants are
viable ifthe mutations do not disturb the functional capacity ofthe virus. This finding
is consistent with the observation that the hypervariable regions are primarily located
on the external envelope glycoprotein, portions of which may not have functional
importance. This finding also implies that the conserved regions of the envelope must
haveessential functional rolesand should beconsidered strategicsites in thedesign ofa
vaccine for AIDS.
VACCINE DEVELOPMENT
No safe and effective vaccine for AIDS is currently available, and several major
obstacles in the course of vaccine development must first be overcome. The observed
genomic diversity among HIV isolates and the possibility that HIV transmission may
occur via infected cells (instead of free virus) are the principal reasons for the
prevailing pessimism regarding our ability to develop a vaccine for AIDS eventually.
In addition to these scientific considerations, we are faced with the lack of a
satisfactory animal model for evaluating HIV infection. The chimpanzee is the only
animal infectable by HIV [52]; however, chimpanzees are an endangered species and
are therefore in short supply and prohibitively expensive. Rhesus macaques are
susceptible to infection by related primate retroviruses, STLV-III [53] and HIV-2
[54], and may represent a good surrogate model system for vaccine testing. The
logistical and time constraints on clinical trials ofcandidate AIDS vaccines, as well as
ethical and legal issues (e.g., product liability), represent additional difficulties
anticipated in the vaccine effort [55].
There are, of course, also findings which can be viewed optimistically for the
development of AIDS vaccine. HIV neutralizing antibodies and antibody-dependent
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cell-mediated cytotoxicity (ADCC)-two important immune parameters in predicting
vaccine efficacy-have been detected in AIDS patients and seropositive individuals
[56-60]. Both neutralizing antibodies and the ADCC response have been found to be
directed against envelope glycoproteins [59,61-64]. Studies to map the precise
envelope domains important in eliciting HIV neutralizing antibodies have shown that
several fall within well-conserved regions [59]. This result suggests that the hetero-
geneity among isolates may not be a major obstacle in vaccine development and that a
single broadly protective vaccine may be possible.
Given the urgency of the AIDS epidemic, several candidate subunit vaccines have
already reached testing in chimpanzees and, in one case, clinical trials in humans,
despite the lack of full understanding of the important viral components to include or
exclude in the vaccine preparation. Several purified or recombinant gpl20 prepara-
tions have been used to immunizechimpanzees. Although specificanti-gpl20 antibody
response developed, none has protected the animals from HIV infection when
challenged [55]. Zagury et al. have begun evaluating in human subjects (Zairians and
the principal investigator) a recombinant vaccine composed ofvaccinia plus the HIV
env gene [65]. Furthermore, despite the lackluster results in chimpanzees, clinical
trials with variouscandidate subunitvaccines areexpected to start in theUnited States
within a year [55].
It is possible that the "shotgun" candidate vaccines will not be protective and that a
rational and stepwise approach to vaccine design will be necessary. An ideal AIDS
vaccine should elicit immune effector responses that are significantly greater than
those induced by the native virus, because the natural responses in HIV-infected
persons are often inadequate. To this end, it will be important to define precisely the
most vulnerable portions of HIV in terms ofantibody neutralization and ADCC. The
"vulnerability" ofa region ofthe virus suggests functional importance; therefore, that
particular domain is likely to fall within invariant regions of HIV. Those critical "soft
spots" which are common to diverse isolates should then be dissected out and properly
packaged for optimal presentation to the immune system ofvaccinees.
ANTI-HIV CHEMOTHERAPY
Approximately five million persons worldwide are already infected with HIV, and a
majorityofthem areexpected toprogress toAIDS orAIDS-relatedcomplex (ARC) in
seven to eight years. The development ofeffective chemotherapy for HIV is therefore
of paramount importance. This difficult task will undoubtedly require a rational and
organized approach to antiviral design, production, and testing. Several features of
HIV pathogenesis should be taken into consideration. First, HIV is a persistent virus
and is likely to require prolonged (possibly life-long) treatment. Therefore, a drug
should ideally be orally bioavailable and reasonably affordable. Second, HIV is
neurotropic, which necessitates adequate drug penetration into the central nervous
system. Third, better understanding of the HIV replication cycle has revealed several
critical virus-specific steps, which are prime targets for antiviral chemotherapy (Table
1). Intense investigative efforts over a short period of time have resulted in the
identification of many potentially useful compounds (Table 1), which have been
recently reviewed elsewhere [66,67].
Antiviral agents with activity against HIV reverse transcriptase include azidothy-
midine-(AZT, also known as zidovudine or Retrovirs) a 3'-azido-3'-deoxy analog of
thymidine. AZT is phosphorylated to a triphosphate form by cellular kinases and
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TABLE 1
Virus-Specific Targets for Anti-HIV Chemotherapy
Stage Potential Intervention Examples References
Binding Interference with gpl20-T4 Anti-gpl20 antibodies [5]
interaction Leu3A, OKT4A antibodies [3-5]
Peptide T [91]
Free T4 molecules
Penetration Alteration in target cell AL721 [92]
membrane fluidity
Inhibition offusogenic do- None
main of HIV env
Reverse Inhibition ofreverse tran- Azidothymidine [66-71]




Integration Inhibition ofintegrase None
Transcription/ Inhibition oftat function None
Translation Inhibition of trs/art function None
Interference with HIV Anti-sense RNA [93]
mRNA
Post-Translational Inhibition ofglycosylation Castanospermine [94]
Processing Unknown Ribavirin (?) [84]
Inhibition ofmyristylation None
Inhibition of HIV protease None
Assembly/Release Inhibition ofassembly or re- Interferon-alpha [87]
lease Interferon-gamma [89]
Ampligen [95]
incorporated into growing DNA chains, thereby preventing chain elongation [68]. It
inhibits HIV replication in vitro at 1-5 ,uM [69], a concentration achievable in vivo.
AZT has an oral bioavailability of60 percent and adequatepenetration intothecentral
nervous system [70,71]. These properties led in 1985 to a phase 1 study in AIDS
patients, which showed that drug recipients had partial reconstitution of immune
responses [70]. This result then prompted a phase 2 multi-center, collaborative,
placebo-controlled trial of AZT in 282 patients with AIDS (those following an initial
episode ofpneumocystis pneumonia) or ARC. The study was prematurely terminated
in September 1986 because of significant differences observed in survival rates [72].
Nineteen patients had died in the placebo group, while only one died among drug
recipients. In addition, there were significantly fewer opportunistic infections in
AZT-treated patients, as well as improvement in their performance scores, skin test
reactivity, and T4 lymphocyte numbers. Suggestions of in vivo antiviral effect with
lower serum antigen (p24) were also evident. Six months after this study, AZT was
licensed for use in this country for adults with AIDS or advanced ARC with
established pneumocystis pneumonia or a blood T4 lymphocyte count of less than
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200/mm3. A preliminary study of AZT in patients with neurologic syndromes
associated with AIDS has demonstrated some benefit [71] and forms the basis for
more extensive investigations in the future.
AZT treatment is associated with considerable toxicity. The development of
megaloblastic anemia is common, and more than 20 percent of the patients on AZT
required blood transfusions [73]. In addition, neutropenia is another frequent (16
percent) complication, as well as headaches. Furthermore, thelong-term side-effects of
this drug are unknown. Another negative feature of AZT is its current cost of
approximately $10,000 per patient per year, which is an enormous financial burden for
patients or third-party payers.
Another nucleotide analog under activeinvestigation is 2'-3'-dideoxycytidine (ddC),
which has also demonstrated considerable in vitro anti-HIV activity [74,75]. It is
phosphorylated by cellular kinases to a triphosphate form that inhibits HIV reverse
transcriptase and its effect can be reversed by deoxycytidine [76]. Phase 1 clinical
trials with ddC are currently in progress in patients with AIDS or ARC [67].
Trisodium phosphonoformate (PFA) is a pyrophosphate analog that also inhibits
HIV reverse transcriptase in vitro [77]. Although the potential clinical use of this
compound has been limited by the lack ofan orally bioavailable form, PFA crosses the
blood-brain barrier and has acceptable toxicity. Phase 1 clinical trials are now in
progress in Sweden, using intravenous infusion of PFA in AIDS and ARC patients
[78,79].
Other inhibitors of HIV reverse transcriptase include HPA-23 [80] and suramin
[81,82]; however, they have not been found to be beneficial in vivo. In fact, in clinical
studies it was concluded that suramin may actually be harmful [82].
Ribavirin is in a synthetic guanosine analog with broad-spectrum antiviral activity
against both DNA and RNA viruses [83] and has demonstrated variable activity
against HIV-1 replication in vitro [84]. Although its mechanismofaction has not been
established, it is converted to ribavirin-5'-triphosphate by cellular enzymes and may
interfere with post-transcriptional processing [83]. A number of clinical trials have
been conducted with ribavirin but have yielded contradictory or controversial results
[85,86].
Interferons appear to act late in the HIV replication cycle and interferons alpha and
beta inhibit HIV replication in vitro in a dose-dependent manner [87,88]. Recombi-
nant human interferon gamma also has some demonstrable effect in vitro [89].
Although the penetration into the central nervous system is poor [67], interferons may
be clinically useful in combination with other anti-HIV agents which act at different
sites ofthe replication cycle.
Combinations of the antiviral agents that act by different mechanisms at various
sites may reduce toxicity by lowering the effective concentration ofan individual drug.
Advantages include enhanced efficacy related to potential additive or synergistic
activity as described for the following drug combinations in vitro [67]: AZT and
interferon-alpha, phosphonoformate and interferon, phosphonoformate and ribavirin,
and ddC and interferon-alpha. Of interest is the finding that one combination, AZT
plus ribavirin, demonstrated antagonism in vitro [90]. Ribavirin appears to inhibit
phosphorylation of AZT to its active triphosphate form. Clinical trials using synergis-
tic combinations ofthese drugs are under way in patients with HIV infections.
Better understanding ofthe biology of HIV and the development or discovery ofthe
antiviral agents listed in Table 1 represent major achievements in medical science, and
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yet much remains to be done. Search for other anti-HIV compounds must continue,
including those which will inhibit other virus-specific sites (e.g., the integrase,
protease, or products of tat or trs/art). Drugs with promising in vitro characteristics,
following appropriate preliminary toxicity and efficacy studies, should be quickly
brought to clinical trials, which must be properly designed and executed. Governmen-
tal regulatory agencies must also facilitate the process of review and licensure while
maintaining high scientific standards. These and other efforts will be necessary to
confront this formidable foe, HIV.
REFERENCES
1. Bowden DL, Lane HC, Fauci AS: Immunopathogenesis of the acquired immunodeficiency syndrome.
Ann Int Med 103:704-709, 1985
2. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, et al: Selective tropism oflymphadenopathy associated
virus (LAV) for helper-inducer T lymphocytes. Science 225:59-64, 1984
3. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4)
antigen is an essential component ofthe receptor for the AIDS retrovirus. Nature 312:763-767, 1984
4. Klatzmann D, Champagne E, Chamaret S, et al: T-lymphocyte T4 molecule behaves as the receptor for
human retrovirus LAV. Nature 312:767-768, 1984
5. McDougal JS, Mawle A, Cort SP, et al: Cellular tropism ofthe human retrovirus HTLV-III/LAV. I.
RoleofT cell activation and expression ofthe T4 antigen. J Immunol 135:3151-3162, 1985
6. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JKA: Binding of HTLV-
III/LAV to T4+ T cells by a complex of the 110 K viral protein and the T4 molecule. Science
231:382-385, 1986
7. Hoxie J, Alper J, Ruekowski J, et al: Alterations in T4 protein and mRNA synthesis in cells infected
with HIV. Science 234:1123-1127, 1986
8. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the
AIDS virus receptor and is expressed in the immune system and brain. Cell 47:333-348, 1986
9. Stein BS, Gowda SD, Lifson JD, et al: pH-independent HIV entry into CD4-positive T cells via virus
envelope fusion to the plasma membrane. Cell 49:659-668, 1987
10. Zagury D, Bernard J, Leonard R, et al: Long-term cultures of HTLV-III infected T cells: a model of
cytopathology ofT-cell depletion in AIDS. Science 231:850-853, 1986
11. Arya S, Guo S, Josephs SF, Wong-Staal F: Trans-activator gene of human T-lymphotropic virus type
III (HTLV-III). Science 229:69-73, 1985
12. Sodroski J, Patarca R, Rosen C, Wong-Staal F, Haseltine W: Location ofthetrans-activating region on
the genome ofhuman T-cell lymphotropic virus type III. Science 299:74-77, 1985
13. Chen ISY: Regulation ofAIDS virus expression. Cell 47:1-2, 1986
14. Sodroski J, Goh WC, Rosen C, Dayton A, Terwilliger E, Haseltine W: A second post-transcriptional
transactivator gene required for HTLV-III replication. Nature 321:412-417, 1986
15.. Feinberg M, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F: HTLV-III expression and production
involve complex regulation at the levels of splicing and translation of viral RNA. Cell 46:807-817,
1986
16. Sodroski J, Goh WC, Rosen C, et al: Replicative and cytopathic potential of HTLV-III/LAV with sor
gene deletions. Science 231:1549-1553, 1986
17. Luciw PA, Cheng-Mayer C, Levy JA: Mutational analysis of the human immunodeficiency virus: the
orf-B region down-regulates virus replication. Proc Natl Acad Sci USA 84:1434-1438, 1987
18. Terwilliger R, Sodroski JG, Rosen CA, Haseltine WA: Effects of mutations within the 3' orf open
reading frame region ofhuman T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and
cytopathogenicity. J Virol 60:754-760, 1986
19. Fisher A, Ratner L, Mitsuya H, et al: Infectious mutants ofHTLV-III with changes in the 3' region and
markedly reduced cytopathic effects. Science 233:655-659, 1986
20. Wong-Staal F, Chanda P, Ghrayeb J: Human immunodeficiency virus: the eighth gene. AIDS Res
Human Retrovirol 3:33-39, 1987
21. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG: AIDS retrovirus induced cytopathology:
giant cell formation and involvement ofCD4 antigen. Science 232:1123-1127, 1986
22. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA: Role of the HTLV-III/LAV envelope in
syncytium formation and cytopathicity. Nature 322:470-474, 1986598 HO AND KAPLAN
23. Lifson JD, Feinberg MB, Reyes GR, et al: Induction of CD4-dependent cell fusion by the HTLV-
III/LAV envelope glycoprotein. Nature 323:725-727, 1986
24. Klatzmann D, Gluckman JC: HIV infection: facts and hypotheses. Immunol Today 7:291-296, 1986
25. Talle MA, Rao PE, Wesberg E, et al: Patterns ofantigenic expression on human monocytes as defined
by monoclonal antibodies. Cell Immunol 78:83-99, 1983
26. Ho DD, Rota TR, Hirsch MS: Infection of monocyte/macrophages by human T-lymphotropic virus
type III. J Clin Invest 77:1712-1715, 1986
27. Nicholson JKA, Gross GD, Callaway CS, McDougal JS: In vitro infection of human monocytes with
human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J
Immunol 137:323-329, 1986
28. Salahuddin SZ, Rose RM, Groopman JE, Markham PD, Gallo RC: Human T lymphotropic virus type
III infection ofhuman alveolar macrophages. Blood 68:281-284, 1986
29. Gartner S, Markovitz DM, Kaplan MH, Gallo RC, Popovic M: The role ofmononuclear phagocytes in
HTLV-III/LAV infection. Science 233:215-219, 1986
30. Smith PD, Ohura K, Masur H, Lane CH, Fauci AS, Wahl SM: Monocyte function in the acquired
immune deficiency syndrome: defective chemotaxis. J Clin Invest 62:136-142, 1985
31. Dinarello CA: Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med
311:1413-1418, 1984
32. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin.
Nature 320:584-588, 1986
33. Serwadda D, Sewankambo N, Carswell J, et al: Slim disease. Lancet ii:849-852, 1985
34. Navia BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features. Ann Neurol
19:517-524, 1986
35. Shaw GM, Harper ME, Hahn BH, etal: HTLV-III infection in brainsofchildren and adults with AIDS
encephalopathy. Science 227:177-182, 1985
36. Ho DD, Rota TR,Schooley RT, etal: Isolation ofHTLV-III fromcerebrospinal fluid and neural tissues
of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J
Med 313:1493-1497, 1985
37. Resnick L, diMarzo-Veronese F, Schupbach J, et al: Intra-blood-brain-barrier synthesis of HTLV-III
specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N
Engl J Med 313:1498-1504, 1985
38. Gabuzda DH, Ho DD, de la Monte SM, Hirsch MS, Rota TR, Sobel RA: Immunohistochemical
identification ofHTLV-Ill antigen in brains ofpatients with AIDS. Ann Neurol 20:289-295, 1986
39. Koenig S, Gendelman HE, Orenstein JM, et al: Detection ofAIDS virus in macrophages in brain tissue
from AIDS patients with encephalopathy. Science 233:1089-1093, 1986
40. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MBA: Cellular localization of human
immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.
Proc Natl Acad Sci USA 83:7089-7093,1986
41. Harper ME, Marselle LM, Gallo RC, Wong-Staal F: Detection of lymphocytes expressing human
T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ
hybridization. Proc Natl Acad Sci USA 83:772-776, 1986
42. Hoxie JA, Haggarty BS, Rackowski JL, Pillsbury N, Levy JA: Persistent noncytopathic infection of
normal human T lymphocytes with AIDS-associated retrovirus. Science 221:1400-1402, 1985
43. Ratner L, Haseltine W, Patarca R, et al: Complete nucleotide sequence ofthe AIDS virus, HTLV-Ill.
Nature 313:277-284, 1985
44. Wain-Hobson S, Sonigo P, Danos 0, Cole S, Alizon M: Nucleotide sequence ofthe AIDS virus, LAV.
Cell 40:9-17, 1985
45. Sanchez-Pescador R, Power MD, Barr PJ, et al: Nucleotide sequence and expression of an AIDS-
associated retrovirus (ARV-2). Science 227:484-492, 1985
46. Muesing MA, Smith DH, Cabradilla CD, Benton CV, LaskyLA,Capon DJ: Nucleicacid structure and
expression ofthe human AIDS/lymphadenopathy retrovirus. Nature 313:450-458, 1985
47. Wong-Staal F, Shaw GM, Hahn BH, et al: Genomic diversity ofhuman T-lymphotropic virus type III
(HTLV-III). Science 229:759-762, 1985
48. Coffin JM: Genetic variation in AIDS viruses. Cell 46:1-4, 1986
49. Starcich BR, Hahn BH, Shaw GM, et al: Identification and characterization ofconserved and variable
regions in the envelope gene ofHTLV-III/LAV, the retrovirus ofAIDS. Cell 45:637-648, 1986
50. Francis DP, Petricciani JC: The prospects for and pathways toward a vaccine for AIDS. N Engl J Med
313:1586-1590, 1985HIV PATHOGENESIS AND CONTROL 599
51. Hahn BH, Shaw GM, Taylor ME, et al: Geneticvariation in HTLV-III/LAV overtimein patients with
AIDS or at risk for AIDS. Science 232:1548-1553, 1986
52. Alter HJ, Eichberg JW, Masur H, et al: Transmission of HTLV-III infection from human plasma to
chimpanzees: an animal model for AIDS. Science 226:549-552, 1984
53. Letvin NL, Daniel MD, Sehgal PK, et al: Induction of AIDS-like disease in macaque monkeys with
T-cell tropic retrovirus STLV-Ill. Science 230:71-73, 1985
54. Fultz PN, Switzer WM, Montagnier L: Infection of rhesus macaques with HIV-2. III International
Conference on AIDS, Washington, DC, 1-5 June 1987. Abstract, p 212
55. Barnes DM: Broad issues debated at AIDS vaccine workshop. Science 236:255-257, 1987
56. Ho DD, Rota TR, Hirsch MS: Antibody to lymphadenopathy-associated virus in AIDS. N Engl J Med
312:649-650, 1985
57. Weiss RA, Clapham PR, Cheingsong-Popov R, et al: Neutralization of human T-lymphotropic virus
type III by sera ofAIDS and AIDS-risk patients. Nature 316:69-72, 1985
58. Robert-Guroff M, Brown M, Gallo RC: HTLV-III-neutralizing antibodies in patients with AIDS and
AIDS-related complex. Nature 316:72-74, 1985
59. Ho DD, Sarngadharan MG, Hirsch MS, et al: Human immunodeficiency virus neutralizing antibodies
recognize several conserved domains on the envelope glycoproteins. J Virol 62:2024-2028, 1987
60. Rook AH, Lane HC, Folks T, et al: Sera from HTLV-III/LAV antibody-positive individuals mediate
antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol
138:1064-1067, 1987
61. Robey WG, Arthur LO, Matthews TJ, etal: Prospects for prevention ofhuman immunodeficiency virus
infection: purified 120-KDa envelope glycoprotein induces neutralizing antibodies. Proc Natl Acad Sci
USA 83:7023-7027, 1986
62. Lasky LA, Groopman JE, Fennie CW, et al: Neutralization of the AIDS retrovirus by antibodies to a
recombinant envelope glycoprotein. Science 233:209-212, 1986
63. Weiss RA, Clapham PR, Weber JN, et al: Variable and conserved neutralization antigens of human
immunodeficiency virus. Nature 324:572-575, 1986
64. Putney SD, Matthews TJ, Robey WG, et al: HTLV-III/LAV-neutralizing antibodies to an E.
coli-produced fragment ofthevirus envelope. Science 234:1392-1395, 1985
65. Zagury D, Leonard R, Fouchard M, et al: Immunization against AIDS in humans. Nature 326:249-
250, 1987
66. Mitsuya H, Broder S: Strategies for antiviral therapy in AIDS. Nature 325:773-778, 1987
67. Hirsch MS, Kaplan JC: Treatment of human immunodeficiency virus infections. Antimicrob Agent
Chemother 31:839-843, 1987
68. Furman PA, Fyfe JA, St. Clair MH, et al: Phosphorylation of3'-azido-3'-deoxythymidine and selective
interaction of the 5'-triphosphate with HIV reverse transcriptase. Proc Natl Acad Sci USA 83:8333-
8337, 1986
69. Mitsuya H, Weinhold KJ, Furman PA, et al: 3'-azido-3'-deoxythymidine (BWA509U): an antiviral
agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/
lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096-7100, 1985
70. Yarchoan R, Klecker RW, Weinhold KJ, et al: Administration of 3'-azido-3'deoxythymidine, an
inhibitorofHTLV-III replication, topatients with AIDSandAIDS-related complex. Lanceti:575-580,
1986
71. Yarchoan R, Berg G, Brouwers P, et al: Response of human immunodeficiency virus associated
neurological disease to 3'-azido-3'-deoxythymidine. Lancet i:132-135, 1987
72. Fischl MA, Richman DD, Grieco MH, et al: The efficacy of AZT in the treatment of patients with
AIDS and ARC. N Engl J Med 317:185-191, 1987
73. Richman D, Fischl MA, Grieco MH, et al: Thetoxicity ofAZT in the treatment ofpatients with AIDS
and ARC. N Engl J Med 317:192-197, 1987
74. Mitsuya H, Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-
lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynu-
cleosides. Proc Natl Acad Sci USA 83:1911-1915, 1986
75. Mitsuya H, Jarret RF, Matsubura M, et al: Long-term inhibition of HTLV III/LAV DNA synthesis
and RNA expression in T cells protected by 2'-3'-dideoxynucleosides in vitro. Proc Natl Acad Sci USA
84:2033-2037, 1987
76. Cooney DA, Dalal M, Mitsuya H, et al: Initial studies on the cellular pharmacology of 2',3'-
dideoxycytidine, an inhibitor ofHTLV III infectivity. Biochem Pharmacol 35:2065-2068, 1986600 HO AND KAPLAN
77. Sandstrom EG, Kaplan JC, Byington RE, Hirsch MS: Inhibition of human T-lymphotropic virus type
III in vitro by phosphonoformate. Lancet i:1480-1482, 1985
78. Farthing CF, Dalgleish AG, Clark A, et al: A pilot study in AIDS and AIDS related complex. AIDS
1:21-25, 1987
79. Gaub J, Pederson C, Poulson A-G, et al: The effect of foscarnet (phosphonoformate) on human
immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS
1:27-33, 1987
80. Rosenbaum W, Dormont D, Spire B, et al: Antimoniotungstate (HPA-23) treatment of three patients
with AIDS and one with prodrome. Lancet i:450-451, 1985
81. Mitsuya H, Popovic M, Yarchoan R, et al: Suramin protection ofT cells in vitro against infectivity and
cytopathic effects of HTLV-III. Science 226:172-174, 1984
82. Kaplan LD, Wolfe PR, Volberding PA, et al: Lack ofresponses to suramin in patients with AIDS and
AIDS-related complex. Am J Med 82:615-620, 1987
83. Gilbert BE, Knight V: Biochemistry and clinical applications of ribavirin. Antimicrob Agents
Chemother 30:201-205, 1986
84. McCormick JB, Getchell JP, Mitchell SW, Hicks DR: Ribavirin suppresses replication of lymphade-
nopathy-associated virus in cultures ofhuman adult T lymphocytes. Lancet ii:1367-1369, 1984
85. Mansell PWA, Heseltine PNR, Roberts RB, etal: Ribavirindelays progressionofthelymphadenopathy
syndrome (LAS) to AIDS. III International Conference on AIDS, Washington, DC, 1-5 June 1987.
Abstract, p 58
86. Crumpacker CS, Bubley G, Loftus J, et al: Longterm treatment ofsevere AIDS and ARC patients with
oral ribavirin: A pilot study. III International Conference on AIDS, Washington, DC, 1-5 June 1987.
Abstract, p 147
87. Ho DD, Hartshorn K, Rota TR, et al: Recombinant human interferon Alpha-A suppresses HTLV-III
replication in vitro. Lancet i:602-604, 1985
88. Yamamoto JK, Barre-Sinoussi V, Bolton NC, et al: Human alpha- and beta-interferon but not gamma
interferon suppress the invitro replication ofLAV, HTLV-III and ARV-2. J Interferon Res 6:143-152,
1986
89. Nakashima H, Toshida T, Haradd S, Yamamoto N: Recombinant human interferon gamma suppresses
HTLV-III replication in vitro. Int J Cancer 38:433-436, 1986
90. Vogt MV, Hartshorn KL, Furman PA, et al: Ribavirin antagonizes the effect of AZT on HIV
replication. Science 235:1376-1379, 1987
91. Pert CB, Hill JM, RuffMR, et al: Octapeptides deduced from the neuropeptide receptor-like pattern of
antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell
infectivity. Proc Natl Acad Sci USA 83:9254-9258, 1986
92. Sarin P, Gallo RC, Scheer DI, et al: Effects ofa novel compound (AL 721) on HTLV-III infectivity in
vitro. N Engl J Med 313:1289-1290, 1985
93. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS: Inhibition of replication and expression of human
T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complemen-
tary to viral RNA. Proc Natl Acad Sci USA 83:4143-4146, 1986
94. Walker BD, Kowalski M, Goh WC, et al: Inhibition of HIV syncytium formation and virus replication
by castanospermine. Proc Natl Acad Sci USA, in press
95. Montefiori DC, Mitchell WM: Antiviral activity ofmismatched double-stranded RNA against human
immunodeficiency virus in vitro. Proc Natl Acad Sci USA 84:2985-2989, 1987